现代治疗时代新辅助化疗后手术及乳房切除术后放疗的II-III期乳腺癌患者临床结局与预后因素
该回顾性研究纳入2005年3月至2013年12月间351例接受新辅助化疗后根治性乳房切除术及乳房切除术后放疗的II或III期乳腺癌患者,中位随访81个月,5年局部区域无复发生存率、无远处转移生存率和总生存率分别为91.3%、69.8%和83.4%;多因素分析显示雌激素受体阳性及腋窝淋巴结病理完全缓解(ypN0)为更好局部区域无复发生存率的显著预后因素,淋巴血管侵犯和临床IIIC期为更差局部区域无复发生存率的独立预后因素,术后腋窝淋巴结转移数目为无远处转移生存率和总生存率的独立预后因素。
要点
- 全组5年局部区域无复发生存率91.3%、无远处转移生存率69.8%、总生存率83.4%。
- 雌激素受体阳性和腋窝淋巴结病理完全缓解(ypN0)与更好局部区域无复发生存率显著相关。
- 术后腋窝淋巴结转移数目是无远处转移生存率和总生存率的独立预后因素。
核心结论
- 研究识别了接受新辅助化疗后乳房切除术及乳房切除术后放疗的局部晚期乳腺癌患者的若干预后因素,其中术后腋窝淋巴结转移数目与总生存率显著相关。
研究设计与样本
- 回顾性评估2005年3月至2013年12月间351例接受新辅助化疗后根治性乳房切除术及乳房切除术后放疗的II或III期乳腺癌患者临床病理因素与结局的关系。
主要发现
- 全组中位随访81个月(范围12-156个月),5年局部区域无复发生存率91.3%、无远处转移生存率69.8%、总生存率83.4%。
- 多因素分析显示雌激素受体阳性和腋窝淋巴结病理完全缓解(ypN0)为更好局部区域无复发生存率的显著预后因素。
- 淋巴血管侵犯和临床IIIC期为更差局部区域无复发生存率的独立预后因素。
- 术后腋窝淋巴结转移数目为无远处转移生存率和总生存率的独立预后因素。
- 激素受体阳性且人表皮生长因子受体2阳性的患者5年局部区域无复发生存率显著更优。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: There are no randomized studies on the indication for postmastectomy radiation therapy (PMRT) in patients who receive neoadjuvant chemotherapy (NAC) followed by a mastectomy. The aim of this study was to determine clinical outcomes and identify reliable prognostic factors in patients with locally advanced breast cancer treated with NAC followed by a mastectomy and PMRT. METHODS AND MATERIALS: We retrospectively evaluated the relationship between clinicopathological factors and outcomes in 351 patients with stage II or III breast cancer who underwent NAC followed by radical mastectomy and PMRT between March 2005 and December 2013. RESULTS: The median follow-up duration was 81 months (Range, 12-156 months). For all patients, the 5-year locoregional recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), and overall survival (OS) rates were 91.3 %, 69.8 %, and 83.4 %, respectively. On multivariate analysis, estrogen-receptor positivity, and complete response of cancer in axillary nodes (ypN0) were significant prognostic factors for better LRFS, while lympho-vascular invasion and clinical stage IIIC were independent prognostic factors for worse LRFS. The number of axillary node metastasesafter surgery was an independent prognostic factor of DMFS and OS. Patients with hormone receptor- and human epidermal growth factor receptor 2 positivity had significantly better 5-year LRFS rates. CONCLUSIONS: We identified several prognostic factors in our study. In particular, the number of axillary node metastases is significantly related to OS.
引用
- Nakajima N, Oguchi M, Kumai Y, et al. Clinical outcomes and prognostic factors in patients with stage II-III breast cancer treated with neoadjuvant chemotherapy followed by surgery and postmastectomy radiation therapy in the modern treatment era. Adv Radiat Oncol. 2018. PMID: 30202796. doi:10.1016/j.adro.2018.04.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。